Search

everythinglearnresearchcommunity

for

Search:↓

Chemotherapy for prostate, bladder, and testicular cancer patients commonly causes hair loss, fatigue, and decreased appetite.

The normal human prostate does not significantly affect blood DHT levels.

New nonsteroidal molecules can potentially increase dihydrotestosterone in neurons by blocking certain enzymes, without affecting prostate and seminal vesicle weight.

The conclusion is that individualized treatment and proper medication use are crucial in men's health, with specific recommendations for ED, BPH, and prostate cancer management.

New compounds were made and tested, with compound 6 showing potential for treating prostate-related diseases.

The document concludes that a compound with potential for treating prostate cancer and hair loss was successfully made and its detailed structure was confirmed.

Enemas can cause septicemia in elderly men with prostate infections.

Young and adult hamsters both respond similarly to testosterone and finasteride treatments, but young hamsters aren't good for testing the inhibitory activity of a specific enzyme.

Finasteride helps reduce heart issues and improves heart function.

Adding a second method to PROTACs could improve cancer treatment.

High uric acid can cause health issues, so managing it with lifestyle changes is important.

Metformin, a diabetes drug, may help prevent and treat various cancers, but more research is needed.

Bolandiol, a synthetic steroid, builds muscle and bone without greatly affecting sex glands, and works differently from other hormones.

Long-term diabetes is linked to lower prostate cancer risk.

Higher BMI is linked to a lower risk of non-aggressive prostate cancer and a higher risk of aggressive prostate cancer.

Men with male pattern baldness have a higher risk of dying from prostate cancer.

PSA could be a marker for hyperandrogenism in women, but more research is needed.

Dutasteride may lower the chance of finding prostate cancer in men with enlarged prostates.

Prostate cancer cells can make their own androgens to activate the androgen receptor, and treatments like abiraterone may increase this ability, suggesting new therapies should target the entire steroid-making pathway.

Researchers developed promising agents for prostate cancer imaging, with the best one showing high potential for clinical use.

5α-reductase inhibitors may prevent prostate cancer but could also raise the risk of more severe cancers.

Dutasteride and finasteride do not significantly affect bone density, blood fats, or blood production, but slightly lower PSA levels and minimally impact sexual function in healthy young men.

Finasteride increases hair weight and count in men with hair loss, with best results after four years.

Finasteride increases hair weight and count in men with hair loss.

The document suggests that targeting the hormone DHT could be a more effective treatment for prostate cancer than targeting testosterone.

Finasteride might lower the risk of low-grade prostate cancer but not high-grade cancer, while alpha-blockers might reduce high-grade cancer risk.

The conclusion suggests that prostate cancer should be classified by castration status and that new therapies targeting androgen receptor signaling show promise.

The document suggests that blocking sweat glands with antiperspirants might allow skin-generated hormones to be absorbed, possibly increasing breast and prostate cancer risk.

Prostate-specific antigen may be a new marker for excess male hormones in women with polycystic ovary syndrome.

Early balding, especially frontal, increases prostate cancer risk; more research needed.